Literature DB >> 2429842

Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.

N H Mulder, D T Sleijfer, J M Smit, E G De Vries, P H Willemse, H S Koops.   

Abstract

Twenty-seven patients with disseminated malignant melanoma were treated with combination chemotherapy consisting of bleomycin, actinomycin D, DTIC and vindesine. There were 4 complete responses in patients with pulmonary metastasis, 5 patients had a partial remission, 2 of them had mainly lung lesions. Toxicity consisted mainly of leuco- and thrombocytopenia of short duration and sporadic severe mucositis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2429842     DOI： 10.1016/0277-5379(86)90377-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  4 in total

1.  Altered cleavage of DNA sequences by bleomycin and its deglycosylated derivative in the presence of actinomycin.

Authors:  C Bailly; A Kénani; M J Waring
Journal:  Nucleic Acids Res       Date:  1997-04-15       Impact factor: 16.971

2.  Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; M J Samson; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

3.  Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

Authors:  N H Mulder; P H Willemse; H Schraffordt Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

4.  Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Authors:  N H Mulder; W T van der Graaf; P H Willemse; H S Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.